Prosecution Insights
Last updated: April 19, 2026

Examiner: BRETZ, COREY LANE

Tech Center 1600 • Art Units: 1635

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
10
Total Applications
Interview Lift
1175
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

7.3%
§101 Eligibility
19.5%
§102 Novelty
29.3%
§103 Obviousness
19.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18025749 RECOMBINANT ADENO ASSOCIATED VIRUS (RAAV) ENCODING GJB2 AND USES THEREOF Non-Final OA President and Fellows of Harvard College
18338150 COMPOSITIONS AND METHODS FOR MODIFYING RNA Non-Final OA The Regents of the University of California
18246981 USE OF A DOUBLE-STRANDED DNA CYTOSINE DEAMINASE FOR MAPPING DNA-PROTEIN INTERACTIONS Non-Final OA University of Washington
18271618 METHOD OF GENE DELIVERY TO RETINAL ASTROCYTES Non-Final OA The United States Government as Represented by The Department of Veterans Affairs
17921338 TARGETED GENOMIC INTEGRATION TO RESTORE NEUROFIBROMIN CODING SEQUENCE IN NEUROFIBROMATOSIS TYPE 1 (NF1) Non-Final OA Duke University
18350077 METHODS AND FORMULATIONS FOR GENE THERAPY, AND FOR COMBINING GENE THERAPY WITH DITPA TREATMENT, OF ALLAN-HERNDON-DUDLEY SYNDROME Non-Final OA Cedars-Sinai Medical Center
18240550 METHODS FOR INCREASED NUCLEIC ACID-GUIDED CELL EDITING Non-Final OA Inscripta, Inc.
17913728 FORSKOLIN-INDUCIBLE PROMOTERS AND HYPOXIA-INDUCIBLE PROMOTERS Non-Final OA ASKLEPIOS BIOPHARMACEUTICAL, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month